About ATAI
ATAI is a company based in Munchen (Germany) founded in 2018. It operates as a B2B. ATAI has raised $386.67 million across 6 funding rounds from investors including Galaxy, George Goldsmith and Apeiron Investment Group. ATAI has completed 2 acquisitions, including Kures and Psyber. ATAI operates in a competitive market with competitors including BridgeBio, Spark Therapeutics, Alnylam, Insitro and Ultragenyx, among others.
- Headquarter Munchen, Germany
- Stage Unicorn
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Unlock access to complete
Unlock access to complete
Funding Insights of ATAI
ATAI has successfully raised a total of $386.67M across 6 strategic funding rounds. The most recent funding activity was a Series D round of $157 million completed in March 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 6
- Last Round Series D — $157.0M
-
First Round
First Round
(01 Jun 2018)
- Investors Count 25
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Mar, 2021 | Amount | Series D - ATAI | Valuation | Apeiron Investment Group , Thiel Capital | |
| Nov, 2020 | Amount | Series C - ATAI | Valuation | Apeiron Investment Group | |
| Apr, 2020 | Amount | Series B - ATAI | Valuation | Steve Jurvetson , Peter Thiel |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in ATAI
ATAI has secured backing from 25 investors, including venture fund, institutional, and angel investors. Prominent investors backing the company include Galaxy, George Goldsmith and Apeiron Investment Group. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture capital firm backed by Christian Angermayer
|
Founded Year | Domain | Location | |
|
Thiel Capital is involved in investment and financial activities.
|
Founded Year | Domain | Location | |
|
VC firm making sector agnostic investments
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by ATAI
ATAI has strategically engaged in corporate development activities, having acquired 2 companies. Notable acquisitions include Kures and Psyber. These strategic investments and acquisitions demonstrate the company's commitment to growth through portfolio expansion, market consolidation, technology integration, and strategic partnerships that enhance competitive positioning and drive long-term value creation.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Opioid-based therapeutics for mood and depression disorders are developed.
|
2015 | ||||
|
Website development and digital marketing services are provided by Psyber.
|
2014 |
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
OVO is recognized as a smart digital payment application.
|
2017 | ||||
|
Bionic investment advisor platform
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 |
Financial Statements - ATAI
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Atai Comparisons
Competitors of ATAI
ATAI operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as BridgeBio, Spark Therapeutics, Alnylam, Insitro and Ultragenyx, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Therapeutics for genetic diseases are developed through targeted interventions.
|
|
| domain | founded_year | HQ Location |
Gene therapies for rare diseases including retinal dystrophies are developed.
|
|
| domain | founded_year | HQ Location |
RNA interference-based therapeutics are developed for multiple disorders.
|
|
| domain | founded_year | HQ Location |
An AI-enabled platform is developed for infectious disease treatment.
|
|
| domain | founded_year | HQ Location |
Therapeutics for rare and ultra-rare metabolic diseases are developed.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Atai
Frequently Asked Questions about ATAI
When was ATAI founded?
ATAI was founded in 2018.
Where is ATAI located?
ATAI is headquartered in Munchen, Germany. It is registered at Munchen, Bayern, Germany.
Is ATAI a funded company?
ATAI is a funded company, having raised a total of $386.67M across 6 funding rounds to date. The company's 1st funding round was a Series B of $24M, raised on Jun 01, 2018.
What does ATAI do?
ATAI a biopharmaceutical company accelerating innovative mental health treatments through providing healthcare solutions, biopharmaceuticals, supporting mental health solutions, and treatment development. Prioritizing client-centric approaches, it ensures high-quality outcomes, innovation, and sustainable practices in its field. It continues to evolve, meeting industry challenges with strategic approaches.
Who are the top competitors of ATAI?
ATAI's top competitors include Spark Therapeutics, BridgeBio and Forge Biologics.
Who are ATAI's investors?
ATAI has 25 investors. Key investors include Galaxy, George Goldsmith, Apeiron Investment Group, Thiel Capital, and Woodline Partners.
What is ATAI's valuation?
The valuation of ATAI is $2B as of Mar 2021.
Book a demo & talk to our team
Share a few details and we’ll reach out to schedule a session.